Skip to main content

Advertisement

Table 2 Rates of severe congestive heart failure in trastuzumab adjuvant trials

From: Targeted therapies in breast cancer: are heart and vessels also being targeted?

  HERA [15] NSABP B-31 [111]   N9831 [16]    BCIRG 006 [112] PACS-04 [113]
Treatment arms Obs 1-year H AC → P AC → PH AC → P AC → P → H AC → PH AC → D AC → DH DCb +H Obs 1- year H
Women at risk (n) 1,698 1,703 872 932 767 718 875 1,050 1,068 1,056 268 260
Cardiac deaths 1 0 1 0 1 1 0 0 0 0 0 0
CHF NYHA class 3-4 (%) 0 13 (0.8) 9 (1.3) 35 (3.9) 2 (0.3) 18 (2.8) 19 (3.3) 4 (0.38) 20 (1.87) 4 (0.38) 1 (0.4) 4 (1.7)
  1. NSABP B-31, cumulative incidence at 5 years; N9831, cumulative incidence at 3 years; no CHF class 3-4 and no cardiac death reported in the FinHer trial. AC, doxorubicin and cyclophosphamide; BCIRG, Breast Cancer International Research Group; Cb, carboplatin; CHF, congestive heart failure; D, docetaxel; H, Herceptin® (trastuzumab); HERA, HERceptin Adjuvant; NSABP, National Surgical Adjuvant Breast and Bowel Project; NYHA, New York Heart Association; Obs, observation; P, paclitaxel; PACS, Protocole Adjuvant dans le cancer du sein.